Novartis boosts cancer immunotherapy research with CoStim acquisition

18-02-2014

Novartis boosts cancer immunotherapy research with CoStim acquisition

Photo: lucarista / Shutterstock.com

Novartis has announced it will acquire biotechnology company CoStim for an undisclosed sum.


Novartis, CoStim, cancer immunotherapy, M&A, PD-1

LSIPR